TY - JOUR T1 - Adoptive Immune Transfer in the Functional Cure of Chronic Hepatitis B: Insights from Hematopoietic Stem Cell Transplantation AU - Ma, He AU - Zheng, Jia-Rui AU - Liu, Xin-Kun AU - Huang, Lin-Xiang AU - Xie, Yan-Di AU - Feng, Bo JF - Journal of Clinical and Translational Hepatology VL - IS - 000 SN - 2310-8819 SP - EP - Y1 - 2026-11-17 DO - 10.14218/JCTH.2026.00549 UR - https://www.xiahepublishing.com/2310-8819/JCTH-2026-00549 AB - Achieving a functional cure for chronic hepatitis B remains challenging, primarily due to the inability to reconstitute effective host immune responses against the virus. The unexpected functional cure of chronic hepatitis B following allogeneic hematopoietic stem cell transplantation provides a unique proof-of-principle model for immune-mediated HBsAg clearance. This review aims to elucidate that the core mechanism underlying hematopoietic stem cell transplantation-mediated HBsAg clearance lies in “adoptive immune transfer”, and to explore design principles and future directions for modern cell-based immunotherapies based on this mechanism. We reviewed available case reports and meta-analytic evidence, acknowledging their limitations, and dissected the immunological mechanisms by which donor-derived hepatitis B virus-specific T and B cells may jointly reconstitute adaptive immunity and break host immune tolerance. We then comparatively evaluated the technical characteristics and limitations of chimeric antigen receptor T cell therapy and T-cell receptor-engineered T-cell therapy. Current engineered T-cell therapies, while translating the core principle of adoptive transfer, exhibit fundamental limitations including monoclonal specificity, inability to remodel the host microenvironment, and absence of durable humoral reconstitution. A broader functional-cure strategy may require adopting the paradigm of synergy and systemic immune reshaping exemplified by hematopoietic stem cell transplantation. Future strategies should develop temporally optimized, multilayered combination therapies, offering a possible pathway for next-generation therapeutics capable of systemically rebuilding antiviral immunity.